Neuroscience Applied最新文献

{"title":"Electroconvulsive therapy reduces suicidality and all-cause mortality in refractory depression: A systematic review and meta-analysis of neurostimulation studies","authors":"Jolein Odermatt,&nbsp;Jan Sarlon,&nbsp;Neysan Schaefer,&nbsp;Sarah Ulrich,&nbsp;Magdalena Ridder,&nbsp;Else Schneider,&nbsp;Undine E. Lang,&nbsp;Timur Liwinski ,&nbsp;Annette B. Brühl","doi":"10.1016/j.nsa.2025.105520","DOIUrl":"10.1016/j.nsa.2025.105520","url":null,"abstract":"<div><div>Depressive disorders are among the most common psychiatric disorders worldwide and associated with half of all suicides. There is robust evidence indicating that both electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) effectively alleviate depressive symptoms in difficult-to-treat depression and enhance patient outcomes. However, there remains ongoing debate regarding their potential roles in preventing suicide and reducing all-cause mortality. Our study aims to investigate the impact of various neurostimulation techniques, including ECT, rTMS, and vagus nerve stimulation (VNS), on reducing suicidality, including suicidal ideation and completed suicides, as well as on overall mortality among individuals diagnosed with depression. In this systematic review and meta-analysis, we searched on MEDLINE via PubMed until January 9, 2024 for randomised controlled trials and controlled observational studies that investigated suicide and all-cause mortality outcomes after neurostimulation treatment for depression.</div><div>Of the 1351 screened records we identified 26 studies eligible for inclusion in our systematic review. We included 11 studies on ECT (involving 17′890 subjects treated with ECT and 25′367 controls receiving treatment as usual), 5 studies on rTMS and 3 studies on VNS in our meta-analysis. In the cumulative cohort, 208 suicide deaths (1.70 %) were observed in the ECT group and 988 suicide deaths (5.02 %) were registered in the control group. Moreover, there were 511 deaths from all causes (3.13 %) in the ECT group, compared to 1325 deaths (6.64 %) in the control group. Thus, treatment with ECT demonstrated a significant 34 % decrease in the odds of suicide (OR 0.66, 95 % CI 0.50–0.88, p = 0.0047) and a 30 % reduction of death from all causes (OR 0.70, 95 % CI 0.62–0.79, p &lt; 0.0001). The standardized mean difference (SMD) for suicidal ideation before and after ECT was −0.58 (95 % CI –0.10 to −1.07, p = 0.0177), suggesting a moderate effect size. We found no significant effect of rTMS on suicidal ideation with an SMD of −0.41 (95 % CI –1.01 – 0.19, p = 0.1795). In patients treated with VNS a 60 % reduction in the odds of death from all causes was observed (OR 0.40, 95 % CI 0.18–0.92, p = 0.0306).</div><div>To conclude, there is consistent observational data supporting the protective effects of ECT against suicide and overall mortality.</div><div>The systematic review protocol is registered online on PROSPERO, CRD42023412887.</div></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105520"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144272574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Schizophrenia management: Systematic review of current medications and Phase-3 agents (2008–2024)","authors":"Salma Abdelmoteleb ,&nbsp;Jayant Totlani ,&nbsp;Salma Ramadan ,&nbsp;Mohamed Salem ,&nbsp;Ashley Meyer ,&nbsp;Tiffany Chang ,&nbsp;Madeline Ewing ,&nbsp;Luiza Freire ,&nbsp;Nathalie Murphy ,&nbsp;Sabrina Renteria ,&nbsp;Romana Dymkoski ,&nbsp;Omer Liran ,&nbsp;Rebecca Hedrick ,&nbsp;Itai Danovitch ,&nbsp;Robert N. Pechnick ,&nbsp;Waguih William IsHak","doi":"10.1016/j.nsa.2025.105507","DOIUrl":"10.1016/j.nsa.2025.105507","url":null,"abstract":"<div><div>This systematic review evaluates psychiatric medications for schizophrenia approved between 2008 and 2024, considering regulatory practices and approvals across multiple regions, including the United States, Europe, and Asian countries. It details the mechanism of action, indications, efficacy, dosing, and adverse effects of each medication. The methodology involved a literature search of the PubMed database for studies published from 2008 to December 31, 2024 on FDA-approved psychiatric medications and Phase 3 pipeline medications, along with additional medications approved in Europe using the keywords “schizophrenia” OR “psychosis” AND “psychopharm∗” OR “medic∗” OR “pharm∗.” An independent assessment was conducted, followed by a consensus on eligible studies for inclusion in the systematic review. From 2008 to December 31, 2024, the FDA approved 29 medications for schizophrenia including 13 long-acting injectables (LAI), in addition to that there are additional three other medications that are available in Europe but not in the United States. Additionally, 8 pipeline medications are currently in Phase-3 clinical trials including one LAI. Each medication is analyzed, and its mechanisms of action, indications, dosing, efficacy, and adverse effects are described. The 13 approved LAIs and the one LAI in the pipeline are detailed in a separate manuscript. This review highlights a significant increase in approved medications for the treatment of schizophrenia, including long-acting injectable formulations that enhance the range of existing oral therapies. Furthermore, new treatments for medication-related movement disorders have been introduced. Innovative developments in Phase-3 trials for schizophrenia medications, including new mechanisms of action and administration routes, promise to transform treatment strategies and enhance patient outcomes.</div></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105507"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virtual reality interventions for cognitive remediation in severe mental illness","authors":"Anna Julia Krupa","doi":"10.1016/j.nsa.2025.105513","DOIUrl":"10.1016/j.nsa.2025.105513","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105513"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143509385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curbing the appetites and restoring the capacity for satisfaction: The impact of GLP-1 agonists on the reward circuitry","authors":"Anna Julia Krupa","doi":"10.1016/j.nsa.2025.105512","DOIUrl":"10.1016/j.nsa.2025.105512","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105512"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Focused Neuroprotection in Parkinson's Disease: Effects of N-Acetylcysteine and MRI-guided Ultrasound Neuromodulation","authors":"R. Caridade Silva ,&nbsp;B. Araújo ,&nbsp;A.C. Vilaça-Ferreira ,&nbsp;C. Vilela ,&nbsp;C. Teixeira ,&nbsp;J. Martins-Macedo ,&nbsp;C. Soares-Guedes ,&nbsp;E.D. Gomes ,&nbsp;S. Mériaux ,&nbsp;B. Larrat ,&nbsp;R. Wade-Martins ,&nbsp;H.J. Fernandes ,&nbsp;F. Teixeira","doi":"10.1016/j.nsa.2025.105496","DOIUrl":"10.1016/j.nsa.2025.105496","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105496"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143637282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemogenetic manipulation of the prefrontal cortex exerts antidepressant effect and controls hippocampal neuroplasticity","authors":"M. Veleanu ,&nbsp;S. Vestring ,&nbsp;J. Weber ,&nbsp;C. Normann ,&nbsp;T. Serchov","doi":"10.1016/j.nsa.2025.105497","DOIUrl":"10.1016/j.nsa.2025.105497","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105497"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143637283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The neurodevelopmental modulator wnt in attention-deficit hyperactivity disorder and the effects of methylphenidate","authors":"C.M. Yde Ohki ,&nbsp;N.M. Walter ,&nbsp;S. Walitza ,&nbsp;E. Grünblatt","doi":"10.1016/j.nsa.2025.105479","DOIUrl":"10.1016/j.nsa.2025.105479","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105479"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143636712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vesicular glutamate transporter 3 deletion in 5-hydroxytryptamine neurons impacts nucleus accumbens dopamine transients","authors":"L.S. Gullino ,&nbsp;L.M. Burgeno ,&nbsp;R. Smausz ,&nbsp;T. Akam ,&nbsp;T. Sharp ,&nbsp;D.M. Bannerman ,&nbsp;M.E. Walton","doi":"10.1016/j.nsa.2025.105463","DOIUrl":"10.1016/j.nsa.2025.105463","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105463"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143636959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience sampling method study in patients with psychosis: associations between smoking, stress and negative affect","authors":"D. Van Der Velde ,&nbsp;S. van der Heijden ,&nbsp;F. Schirmbeck ,&nbsp;J. Vermeulen ,&nbsp;L. de Haan","doi":"10.1016/j.nsa.2025.105411","DOIUrl":"10.1016/j.nsa.2025.105411","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105411"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143637613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional mapping of brain pathways involved in the gut microbial modulation of social behaviour","authors":"M. Depret ,&nbsp;N. Van Munsteren ,&nbsp;M. Thabault ,&nbsp;P. Fitzgerald ,&nbsp;J.F. Cryan ,&nbsp;L. Katona","doi":"10.1016/j.nsa.2025.105461","DOIUrl":"10.1016/j.nsa.2025.105461","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105461"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143637101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}